Solasia Pharma K.K. (4597.T)
JPY 34.0
(6.25%)
JPY 34.0
(6.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 617 Million JPY | -43.5% |
| 2022 | 1.09 Billion JPY | 95.35% |
| 2021 | 559 Million JPY | 23.13% |
| 2020 | 454 Million JPY | -65.34% |
| 2019 | 1.31 Billion JPY | 311.95% |
| 2018 | 318 Million JPY | -22.6% |
| 2017 | 410.85 Million JPY | -18.05% |
| 2016 | 501.31 Million JPY | 118.47% |
| 2015 | 229.46 Million JPY | 1819.9% |
| 2014 | 11.95 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 11 Million JPY | -26.67% |
| 2024 Q2 | 60 Million JPY | 445.45% |
| 2023 Q4 | 15 Million JPY | -79.45% |
| 2023 Q1 | 220 Million JPY | -63.76% |
| 2023 Q2 | 309 Million JPY | 40.45% |
| 2023 Q3 | 73 Million JPY | -76.38% |
| 2023 FY | 617 Million JPY | -43.5% |
| 2022 Q3 | 295 Million JPY | 288.16% |
| 2022 Q1 | 113 Million JPY | -59.06% |
| 2022 FY | 1.09 Billion JPY | 95.35% |
| 2022 Q4 | 607 Million JPY | 105.76% |
| 2022 Q2 | 76 Million JPY | -32.74% |
| 2021 Q3 | 5 Million JPY | -97.31% |
| 2021 FY | 559 Million JPY | 23.13% |
| 2021 Q1 | 91 Million JPY | -45.51% |
| 2021 Q2 | 186 Million JPY | 104.4% |
| 2021 Q4 | 276 Million JPY | 5420.0% |
| 2020 Q2 | 84 Million JPY | -46.15% |
| 2020 Q3 | 47 Million JPY | -44.05% |
| 2020 FY | 454 Million JPY | -65.34% |
| 2020 Q1 | 156 Million JPY | -84.69% |
| 2020 Q4 | 167 Million JPY | 255.32% |
| 2019 Q3 | 160 Million JPY | 131.88% |
| 2019 Q1 | 61 Million JPY | -70.67% |
| 2019 FY | 1.31 Billion JPY | 311.95% |
| 2019 Q4 | 1.01 Billion JPY | 536.88% |
| 2019 Q2 | 69 Million JPY | 13.11% |
| 2018 Q4 | 208 Million JPY | 700.0% |
| 2018 Q3 | 26 Million JPY | -65.79% |
| 2018 Q2 | 76 Million JPY | 985.71% |
| 2018 Q1 | 7 Million JPY | 420.83% |
| 2018 FY | 318 Million JPY | -22.6% |
| 2017 Q1 | 3.57 Million JPY | -98.81% |
| 2017 Q2 | 2.05 Million JPY | -42.64% |
| 2017 Q3 | 403.87 Million JPY | 19572.38% |
| 2017 FY | 410.85 Million JPY | -18.05% |
| 2017 Q4 | 1.34 Million JPY | -99.67% |
| 2016 Q4 | 300 Million JPY | 0.0% |
| 2016 FY | 501.31 Million JPY | 118.47% |
| 2016 Q3 | - JPY | -100.0% |
| 2016 Q2 | 1.31 Million JPY | -99.34% |
| 2016 Q1 | 200 Million JPY | 714.2% |
| 2015 Q3 | 1.9 Million JPY | 0.0% |
| 2015 Q4 | 24.56 Million JPY | 1191.48% |
| 2015 FY | 229.46 Million JPY | 1819.9% |
| 2014 FY | 11.95 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 99.007% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.986% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 99.804% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 99.858% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 92.027% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 99.584% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 99.144% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 99.917% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 95.027% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 99.565% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 99.4% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 98.886% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 97.993% |
| Tsumura & Co. | 150.84 Billion JPY | 99.591% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 99.184% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 98.871% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 99.729% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 98.491% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 99.185% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 99.484% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | 87.758% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 98.684% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | 88.962% |
| MedRx Co., Ltd | 26 Million JPY | -2273.077% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 94.386% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 99.018% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 99.651% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -909.622% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.958% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 97.212% |